Crossmark

Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia

Crossref DOI link: https://doi.org/10.1016/j.htct.2025.106234

Published Print: 2026-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Nascimento, Aline do https://orcid.org/0000-0001-8801-6012
Curado, Daniel da Silva Pereira https://orcid.org/0000-0002-5965-4194
Montezuma, Thais https://orcid.org/0000-0001-7669-5732
Barbosa, Wallace Breno https://orcid.org/0000-0003-2702-1533
Machado-Rugolo, Juliana https://orcid.org/0000-0003-3984-4959
Fachi, Mariana Millan https://orcid.org/0000-0001-5918-4738
Funding

Funding for this research was provided by:

Ministério da Saúde
License Information

Text and Data Mining valid from 2026-01-01

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2025-11-21
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2025.106234

Content Type: article

Copyright: © 2025 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below